Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Bipolar Disorder AND Major Depressive Disorder AND Placebo

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    33 result(s) found for: Bipolar Disorder AND Major Depressive Disorder AND Placebo. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2019-004440-29 Sponsor Protocol Number: ITI-007-403 Start Date*: 2020-05-21
    Sponsor Name:Intra-Cellular Therapies, Inc. (ITI)
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of Lumateperone Monotherapy in the Treatment of Patients with Major Depressive Episodes...
    Medical condition: Major depressive episodes (MDEs) associated with Bipolar I or Bipolar II Disorder (Bipolar Depression) with mixed features or major depressive disorder (MDD) with mixed features
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10004936 Bipolar depression LLT
    21.1 100000004873 10081270 Major depressive disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2021-002126-24 Sponsor Protocol Number: SEP380-301 Start Date*: 2022-02-02
    Sponsor Name:Sunovion Pharmaceuticals Inc.
    Full Title: A Multi-region, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating SEP-4199 Controlled Release (CR) for the Treatment of Major Depressive Episode Associated ...
    Medical condition: Major Depressive Episode Associated with Bipolar I Disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10004939 Bipolar I disorder PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Prematurely Ended) SK (Prematurely Ended) HR (Completed)
    Trial results: View results
    EudraCT Number: 2013-003038-34 Sponsor Protocol Number: D1002001 Start Date*: 2015-07-07
    Sponsor Name:Sumitomo Dainippon Pharma Co., Ltd.
    Full Title: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of SM-13496 for the Treatment of Bipolar I Depression
    Medical condition: Bipolar I depression
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004873 10004936 Bipolar depression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2008-007457-13 Sponsor Protocol Number: D1050236 Start Date*: 2009-10-21
    Sponsor Name:Sunovion Pharmaceuticals, Inc.
    Full Title: A Randomized, 6-Week, Double-Blind, Placebo-controlled, Fixed-Flexible-Dose, Parallel-Group Study of Lurasidone in the Treatment of Bipolar I Depression
    Medical condition: Bipolar depression
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10004936 Bipolar depression LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2010-023623-26 Sponsor Protocol Number: C10953/3073 Start Date*: 2011-07-14
    Sponsor Name:Cephalon, Inc.
    Full Title: A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/day) as Adjunctive Therapy in Adults With Major Depressio...
    Medical condition: Major Depression Associated With Bipolar I Disorder
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004873 10004911 Bipolar affective disorder, depressed LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) FI (Completed) DE (Completed) IT (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2010-019778-34 Sponsor Protocol Number: D1050292 Start Date*: 2011-03-14
    Sponsor Name:Sunovion, Inc.
    Full Title: A RANDOMIZED, 6-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED, FLEXIBLE-DOSE, PARALLEL-GROUP STUDY OF LURASIDONE ADJUNCTIVE TO LITHIUM OR DIVALPROEX FOR THE TREATMENT OF BIPOLAR I DEPRESSION IN SUBJECTS ...
    Medical condition: Bipolar disorder
    Disease: Version SOC Term Classification Code Term Level
    12.1 10004936 Bipolar depression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) LT (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2008-007482-23 Sponsor Protocol Number: D1050235 Start Date*: 2009-10-21
    Sponsor Name:Sunovion Pharmaceuticals, Inc.
    Full Title: A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Flexible-Dose, Parallel-Group Study of Lurasidone Adjunctive to Lithium or Divalproex for the Treatment of Bipolar I Depression
    Medical condition: Bipolar depression
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10004936 Bipolar depression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2012-002954-21 Sponsor Protocol Number: KETIVEDI2001 Start Date*: 2013-05-14
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: An exploratory, blinded, randomized, placebo-controlled study in subjects with depressive disorder to investigate the effect of minocycline on relapse after successful intravenous ketamine/minocycl...
    Medical condition: Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    16.1 10037175 - Psychiatric disorders 10004940 Bipolar II disorder PT
    16.1 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) NL (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-002106-36 Sponsor Protocol Number: JNJ-DEP Start Date*: 2016-01-11
    Sponsor Name:Clinirx Tangent Research
    Full Title: The effects of JNJ-39393406 on psychometric performance and residual depressive symptoms in 80 patients with unipolar or bipolar depression: a phase II exploratory add-on double blind placebo contr...
    Medical condition: Unipolar and bipolar depression
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004873 10004936 Bipolar depression LLT
    19.0 100000004873 10045543 Unipolar depression LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: RO (Suspended by CA)
    Trial results: (No results available)
    EudraCT Number: 2005-004881-17 Sponsor Protocol Number: CL3-20098-047 Start Date*: 2006-05-01
    Sponsor Name:Institut de Recherches Internationales Servier [...]
    1. Institut de Recherches Internationales Servier
    2. Laboratorios Servier S.L. (For Spain only)
    Full Title: Efficacy and safety of agomelatine (25 mg/day with potential adjustment at 50 mg/day) given orally compared to placebo, in addition to a mood stabilizer in Bipolar I patients with a current major d...
    Medical condition: Major depressive episode in the framework of bipolar disorder
    Disease: Version SOC Term Classification Code Term Level
    7.0 10004939 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) NL (Completed) ES (Completed) FI (Completed) DK (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-002317-58 Sponsor Protocol Number: ITI-007-404 Start Date*: 2018-03-09
    Sponsor Name:Intra-Cellular Therapies, Inc. (ITI)
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of Lumateperone Monotherapy in the Treatment of Patients with Major Depressive Episodes...
    Medical condition: Bipolar I or Bipolar II Disorder (Bipolar Depression)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10004936 Bipolar depression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2007-002551-17 Sponsor Protocol Number: 12022A Start Date*: 2007-12-14
    Sponsor Name:H. Lundbeck a/s
    Full Title: Randomised, double-blind, parallel-group, placebo-controlled, and active referenced study of Lu AA34893 to evaluate the efficacy and safety of three doses Lu AA34893 and quetiapine versus placebo i...
    Medical condition: Bipolar Depression at Phase II study with patients. Lu AA34893 is a novel compound under development by H. Lundbeck A/S as an antidepressant.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10004936 Bipolar depression LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) AT (Prematurely Ended) FR (Completed) GB (Prematurely Ended) SE (Prematurely Ended) DE (Completed) LT (Prematurely Ended) SK (Completed)
    Trial results: View results
    EudraCT Number: 2021-004790-31 Sponsor Protocol Number: 55308942BIP2001 Start Date*: 2022-05-31
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Stratified, Double-blind, Placebo-Controlled Study to Investigate the Efficacy, Safety and Tolerability of JNJ-55308942 in Bipolar Depression
    Medical condition: Bipolar Depression
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10004936 Bipolar depression LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing) PL (Completed)
    Trial results: View results
    EudraCT Number: 2007-007555-14 Sponsor Protocol Number: C10953/2032/DP/US Start Date*: 2008-08-15
    Sponsor Name:Cephalon, Inc.
    Full Title: An 8-Week, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/day) as Adjunctive Therapy in Adults With Major ...
    Medical condition: Major Depression Associated With Bipolar I Disorder
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057840 Major depression LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2011-002334-39 Sponsor Protocol Number: RGH-MD-56 Start Date*: 2012-04-09
    Sponsor Name:Forest Research Institute, Inc
    Full Title: A Double-blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Cariprazine in Patients With Bipolar Depression
    Medical condition: Bipolar I Disorder Major Depressive Episode
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10004939 Bipolar I disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2005-004357-94 Sponsor Protocol Number: NPS-2005-1 Start Date*: 2006-01-20
    Sponsor Name:Nordfjord Psychiatric Centre
    Full Title: Escitalopram in bipolar depression: a placebo-controlled study of acute and maintenance treatment.
    Medical condition: Patients with bipolar disorder in a depressive episode are randomised to receive escitalopram or placebo for eight weeks. Responders to escitalopram are re-randomised to placebo or escitalopram for...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-002108-11 Sponsor Protocol Number: SEP380-303 Start Date*: 2022-02-10
    Sponsor Name:Sunovion Pharmaceuticals Inc.
    Full Title: A 12-Month Open-label Extension Study to Evaluate the Long-term Safety, Tolerability, and Effectiveness of SEP-4199 Controlled Release (CR) for the Treatment of Major Depressive Episode Associated ...
    Medical condition: Major Depressive Episodes Associated with Bipolar I Disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10004939 Bipolar I disorder PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Prematurely Ended) SK (Prematurely Ended) HR (Completed)
    Trial results: View results
    EudraCT Number: 2018-000103-16 Sponsor Protocol Number: SEP380-201 Start Date*: 2018-11-26
    Sponsor Name:SUNOVION PHARMACEUTICALS INC.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of SEP-4199 for the Treatment of Major Depressive Episode Associated with Bipolar I Disorder
    Medical condition: Major Depressive Episodes Associated with Bipolar I Disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10004939 Bipolar I disorder PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Completed) SK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2009-016648-38 Sponsor Protocol Number: C10953/3074 Start Date*: 2010-08-06
    Sponsor Name:Cephalon, Inc.
    Full Title: A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With ...
    Medical condition: Major Depression Associated With Bipolar I Disorder
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) BG (Prematurely Ended) ES (Completed) DE (Prematurely Ended) FI (Completed) SK (Prematurely Ended) HU (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-001357-10 Sponsor Protocol Number: TAK-375SL_301 Start Date*: 2012-11-14
    Sponsor Name:Takeda Global Research & Development Centre (Europe) Ltd (TGRD)
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) 0.1 mg a...
    Medical condition: Acute Depressive Episodes associated with Bipolar 1 Disorder
    Disease: Version SOC Term Classification Code Term Level
    15.0 10037175 - Psychiatric disorders 10004939 Bipolar I disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) CZ (Prematurely Ended) PL (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jun 03 18:46:19 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA